AZN.UK

11,196

-1.63%↓

GSK

1,449

-0.96%↓

HLN.UK

395.2

+0.56%↑

INDV

721.5

-2.96%↓

AZN.UK

11,196

-1.63%↓

GSK

1,449

-0.96%↓

HLN.UK

395.2

+0.56%↑

INDV

721.5

-2.96%↓

AZN.UK

11,196

-1.63%↓

GSK

1,449

-0.96%↓

HLN.UK

395.2

+0.56%↑

INDV

721.5

-2.96%↓

AZN.UK

11,196

-1.63%↓

GSK

1,449

-0.96%↓

HLN.UK

395.2

+0.56%↑

INDV

721.5

-2.96%↓

AZN.UK

11,196

-1.63%↓

GSK

1,449

-0.96%↓

HLN.UK

395.2

+0.56%↑

INDV

721.5

-2.96%↓

Search

PureTech Health Plc

Geschlossen

138.8 -0.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

135

Max

141.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

Verkäufe

288K

Gewinnspanne

-14,504.514

Angestellte

90

EBITDA

-65M

Dividenden

By Dow Jones

Nächstes Ergebnis

24. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

345M

Vorheriger Eröffnungskurs

139.52

Vorheriger Schlusskurs

138.8

PureTech Health Plc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Apr. 2025, 23:55 UTC

Heiße Aktien

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2. Apr. 2025, 22:50 UTC

Wichtige Markttreiber

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2. Apr. 2025, 21:08 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2. Apr. 2025, 21:00 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2. Apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2. Apr. 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2. Apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2. Apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2. Apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2. Apr. 2025, 22:43 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2. Apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2. Apr. 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2. Apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2. Apr. 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2. Apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2. Apr. 2025, 20:53 UTC

Ergebnisse

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2. Apr. 2025, 20:52 UTC

Ergebnisse

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer-Vergleich

Kursveränderung

PureTech Health Plc Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.